Profhilo® — Injectable Hyaluronic Acid for Bio Remodeling Skin

Launched in 2015, Profhilo® is a novel HA preparation that is based on stable hybrid cooperative complexes of high- and low-molecular weight Hyaluronic Acid, made with an innovative thermal production process patented by IBSA.

The production process starts with a simple mixture of 32 mg of high-molecular-weight HA (1100-1400 kDa) and 32 mg of low-molecular-weight HA (80-100 kDa). The mixture is then stabilised by the abovementioned thermal process, which does not use crosslinking agents and consists of, first, a high-temperature step, followed by a low-temperature step.

The result is a product that boosts both remodeling and repair processes of tissues, even when scarring has occurred. It also improves skin laxity of the face, neck, and body.

PROFHILO® is indicated for the treatment of the face and body, in particular for the treatment of the malar-zygomatic and submalar areas. An initial cycle of two sessions at 30-day intervals is recommended, followed if necessary by maintenance procedures every 2 months. However, it is suggested to evaluate the specific PROFHILO® protocol according to the patients' degree of aging.

The product shows unique characteristics, such as a high HA concentration (64 mg/2 mL), ideal manageability, optimal tissue diffusion and low viscosity, and with a predominance of fluidity over elasticity. Moreover, HyCoCos has a high biocompatibility profile.

Compared to other native HA formulations, HyCoCos show the potential for a more effective global bio remodeling performance, and the simultaneous presence of high- and low-molecular-weight hyaluronan makes it a medical device that can be used in both esthetic and regenerative medicine. As proven by the research, the hybrid complex formed by H-HA and L-HA promotes wound healing of human keratinocytes in vitro better than HA alone. Moreover, this particular combination increases the expression levels of type I and type III collagens as well as elastin.

In vitro and clinical trials have confirmed the innovative characteristics of the product. Therefore, after 3 years of marketing use, the manufacturer has reviewed the postmarketing safety data to provide a full and extensive description of the product profile.

Injection Technique
IBSA recommends 2 sessions with a one-month interval by means of the BAP (Bio Esthetic Points) Techniques to minimize the risks and maximize the product's flowability.

Five points for intradermal administration of PROFHILO® are identified as follows:

1. Zygomatic Protrusion. It is recommended to stay at least 2 cm away from the lateral canthus (external corner) of the eye.

2. Nasal Base. A line connecting the nostril and tragus and a perpendicular line starting from the pupil must be drawn to locate the injection point at the intersection of the 2 lines.

3. Tragus. It is recommended to stay at least 1 cm anterior to the inferior margin of the tragus.

4. Chin. A vertical line at the center of the chin and a perpendicular line one-third of the distance from the top of the vertical line have to be drawn. From the point of intersection, it is indicated to move 1.5 cm towards the oral commissure to locate the injection point.

5. Mandibular angle. The fifth point is located 1 cm above the mandibular angle.

Then, 0.2 ml of product with the bolus technique must be injected in the deep dermal/subcutaneous levels.

Injections should be followed by a gentle massage.

Source: The National Center for Biotechnology Information